Research efforts primarily concern renal pathology and involve: 1) basic research in mechanisms and pathophysiology of progression of chronic renal disease; including regression/remodeling of sclerosis; 2) basic research in mechanisms and pathophysiology of the renin angiotensin system; and 3) applied renal pathology with emphasis on prognostic features in minimal change disease/focal glomerulosclerosis.

Chronic rat animal models and knock-out mice are used to investigate the interactions of fibrotic and thrombotic mechanisms. Our work focuses on contributions of the renin angiotensin system to structural damage, and its interactions with other growth factors, and with mechanisms of thrombosis (i.e. plasmin/plasminogen activator system). Approaches include classical pathology, molecular biology and functional assessments.


The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Macrophage polarization by angiotensin II-type 1 receptor aggravates renal injury-acceleration of atherosclerosis. Yamamoto S, Yancey PG, Zuo Y, Ma LJ, Kaseda R, Fogo AB, Ichikawa I, Linton MF, Fazio S, Kon V (2011) Arterioscler Thromb Vasc Biol 31(12): 2856-64
    › Primary publication · 21979434 (PubMed) · PMC3227118 (PubMed Central)
  2. Cells derived from young bone marrow alleviate renal aging. Yang HC, Rossini M, Ma LJ, Zuo Y, Ma J, Fogo AB (2011) J Am Soc Nephrol 22(11): 2028-36
    › Primary publication · 21965376 (PubMed) · PMC3231782 (PubMed Central)
  3. Podocyte injury damages other podocytes. Matsusaka T, Sandgren E, Shintani A, Kon V, Pastan I, Fogo AB, Ichikawa I (2011) J Am Soc Nephrol 22(7): 1275-85
    › Primary publication · 21719786 (PubMed) · PMC3137575 (PubMed Central)
  4. The targeted podocyte. Fogo AB (2011) J Clin Invest 121(6): 2142-5
    › Primary publication · 21606599 (PubMed) · PMC3104780 (PubMed Central)
  5. Protective effects of PPARĪ³ agonist in acute nephrotic syndrome. Zuo Y, Yang HC, Potthoff SA, Najafian B, Kon V, Ma LJ, Fogo AB (2012) Nephrol Dial Transplant 27(1): 174-81
    › Primary publication · 21565943 (PubMed) · PMC3276311 (PubMed Central)
  6. Induction of podocyte-derived VEGF ameliorates podocyte injury and subsequent abnormal glomerular development caused by puromycin aminonucleoside. Ma J, Matsusaka T, Yang HC, Zhong J, Takagi N, Fogo AB, Kon V, Ichikawa I (2011) Pediatr Res 70(1): 83-9
    › Primary publication · 21451433 (PubMed) · PMC3113658 (PubMed Central)
  7. Angiotensin type 1 receptor modulates macrophage polarization and renal injury in obesity. Ma LJ, Corsa BA, Zhou J, Yang H, Li H, Tang YW, Babaev VR, Major AS, Linton MF, Fazio S, Hunley TE, Kon V, Fogo AB (2011) Am J Physiol Renal Physiol 300(5): F1203-13
    › Primary publication · 21367915 (PubMed) · PMC3094053 (PubMed Central)
  8. Models of chronic kidney disease. Yang HC, Zuo Y, Fogo AB (2010) Drug Discov Today Dis Models 7(1-2): 13-19
    › Primary publication · 21286234 (PubMed) · PMC3030258 (PubMed Central)
  9. Glomerular sclerosis is prevented during urinary tract obstruction due to podocyte protection. Matsusaka T, Kobayashi K, Kon V, Pastan I, Fogo AB, Ichikawa I (2011) Am J Physiol Renal Physiol 300(3): F792-800
    › Primary publication · 21177778 (PubMed) · PMC3064125 (PubMed Central)
  10. Navigating the challenges of fibrosis assessment: land in sight? Fogo AB, Alpers CE (2011) J Am Soc Nephrol 22(1): 11-3
    › Primary publication · 21127139 (PubMed)
  11. Cell senescence in the aging kidney. Yang H, Fogo AB (2010) J Am Soc Nephrol 21(9): 1436-9
    › Primary publication · 20705707 (PubMed)
  12. PPARĪ³ and chronic kidney disease. Fogo AB (2011) Pediatr Nephrol 26(3): 347-51
    › Primary publication · 20676693 (PubMed)
  13. The glomerulus--a view from the inside--the endothelial cell. Fogo AB, Kon V (2010) Int J Biochem Cell Biol 42(9): 1388-97
    › Primary publication · 20541032 (PubMed)
  14. The PPARgamma agonist pioglitazone ameliorates aging-related progressive renal injury. Yang HC, Deleuze S, Zuo Y, Potthoff SA, Ma LJ, Fogo AB (2009) J Am Soc Nephrol 20(11): 2380-8
    › Primary publication · 19797472 (PubMed) · PMC2799181 (PubMed Central)
  15. Renal dysfunction potentiates foam cell formation by repressing ABCA1. Zuo Y, Yancey P, Castro I, Khan WN, Khan W, Motojima M, Ichikawa I, Fogo AB, Linton MF, Fazio S, Kon V (2009) Arterioscler Thromb Vasc Biol 29(9): 1277-82
    › Primary publication · 19667109 (PubMed) · PMC2748735 (PubMed Central)
  16. PAI-1 and kidney fibrosis. Ma LJ, Fogo AB (2009) Front Biosci (Landmark Ed) 14(6): 2028-41
    › Primary publication · 19273183 (PubMed) · PMC4848749 (PubMed Central)
  17. Potential for peroxisome proliferator-activated receptor-gamma agonists in progression: beyond metabolism. Fogo AB (2008) Curr Opin Nephrol Hypertens 17(3): 282-5
    › Primary publication · 18408479 (PubMed)
  18. Mechanisms of progression of chronic kidney disease. Fogo AB (2007) Pediatr Nephrol 22(12): 2011-22
    › Primary publication · 17647026 (PubMed) · PMC2064942 (PubMed Central)
  19. Angiotensin inhibition decreases progression of advanced atherosclerosis and stabilizes established atherosclerotic plaques. Suganuma E, Babaev VR, Motojima M, Zuo Y, Ayabe N, Fogo AB, Ichikawa I, Linton MF, Fazio S, Kon V (2007) J Am Soc Nephrol 18(8): 2311-9
    › Primary publication · 17634441 (PubMed)
  20. Alphav beta6 integrin regulates renal fibrosis and inflammation in Alport mouse. Hahm K, Lukashev ME, Luo Y, Yang WJ, Dolinski BM, Weinreb PH, Simon KJ, Chun Wang L, Leone DR, Lobb RR, McCrann DJ, Allaire NE, Horan GS, Fogo A, Kalluri R, Shield CF, Sheppard D, Gardner HA, Violette SM (2007) Am J Pathol 170(1): 110-25
    › Primary publication · 17200187 (PubMed) · PMC1762706 (PubMed Central)
  21. Plasminogen activator inhibitor-1 in chronic kidney disease: evidence and mechanisms of action. Eddy AA, Fogo AB (2006) J Am Soc Nephrol 17(11): 2999-3012
    › Primary publication · 17035608 (PubMed)
  22. Antiatherogenic effects of angiotensin receptor antagonism in mild renal dysfunction. Suganuma E, Zuo Y, Ayabe N, Ma J, Babaev VR, Linton MF, Fazio S, Ichikawa I, Fogo AB, Kon V (2006) J Am Soc Nephrol 17(2): 433-41
    › Primary publication · 16371432 (PubMed)
  23. Proteomic patterns and prediction of glomerulosclerosis and its mechanisms. Xu BJ, Shyr Y, Liang X, Ma LJ, Donnert EM, Roberts JD, Zhang X, Kon V, Brown NJ, Caprioli RM, Fogo AB (2005) J Am Soc Nephrol 16(10): 2967-75
    › Primary publication · 16079267 (PubMed)
  24. Angiotensin II amplifies macrophage-driven atherosclerosis. Nobuhiko A, Suganuma E, Babaev VR, Fogo A, Swift LL, Linton MF, Fazio S, Ichikawa I, Kon V (2004) Arterioscler Thromb Vasc Biol 24(11): 2143-8
    › Primary publication · 15374850 (PubMed)
  25. Transforming growth factor-beta-dependent and -independent pathways of induction of tubulointerstitial fibrosis in beta6(-/-) mice. Ma LJ, Yang H, Gaspert A, Carlesso G, Barty MM, Davidson JM, Sheppard D, Fogo AB (2003) Am J Pathol 163(4): 1261-73
    › Primary publication · 14507636 (PubMed) · PMC1868298 (PubMed Central)
  26. Absence of angiotensin II type 1 receptor in bone marrow-derived cells is detrimental in the evolution of renal fibrosis. Nishida M, Fujinaka H, Matsusaka T, Price J, Kon V, Fogo AB, Davidson JM, Linton MF, Fazio S, Homma T, Yoshida H, Ichikawa I (2002) J Clin Invest 110(12): 1859-68
    › Primary publication · 12488436 (PubMed) · PMC151648 (PubMed Central)